Lynx1 Capital Management
$866M 13F equity value
29 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Lynx1 Capital Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| GHRS | GH RESEARCH PLC | 13,263,288 | $357M | 41.2% |
| CGEM | CULLINAN THERAPEUTICS INC | 8,963,500 | $163M | 18.9% |
| STOK | STOKE THERAPEUTICS INC | 4,038,404 | $132M | 15.3% |
| AGIO | AGIOS PHARMACEUTICALS INC | 3,408,937 | $127M | 14.6% |
| CCCC | C4 THERAPEUTICS INC | 7,326,691 | $34M | 4.0% |
| KRRO | KORRO BIO INC | 1,538,296 | $20M | 2.3% |
| TCRX | TSCAN THERAPEUTICS INC | 8,019,148 | $8M | 0.9% |
| DTIL | PRECISION BIOSCIENCES INC | 950,466 | $7M | 0.9% |
| NEUP | NEUPHORIA THERAPEUTICS INC | 875,328 | $4M | 0.4% |
| PASG | PASSAGE BIO INC | 673,759 | $3M | 0.4% |
Track Lynx1 Capital Management's 13F portfolio: $866M in reported holdings, 29 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}